Video

Emerging Agents for R/R CLL

Author(s):

William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Related Videos
David C. Fisher, MD
Nitin Jain, MD
Kathleen A. Dorritie, MD
Alexey Danilov, MD, PhD
John Seymour, MBBS, FRACP, PhD
A panel of 5 experts on CLL
A panel of 5 experts on CLL
A panel of 5 experts on CLL
Mazyar Shadman, MD, MPH
Jean L. Koff, MD, MS
Related Content
David C. Fisher, MD, of Dana-Farber Cancer Institute
October 21st 2024

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Ryan Jacobs, MD, Levine Cancer Institute
October 12th 2024

Fixed-Duration Ibrutinib/Venetoclax Elicits Meaningful Survival Benefit in High-Risk CLL/SLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Javier Pinilla-Ibarz, MD, PhD, senior member, head, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center
September 9th 2024

Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL

William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features